Vext Science (VEXT) AI Stock Analysis

• Market Cap: C$69.35M
• Dividend Yield: N/A
• Average Volume (3M): 40.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: 43.56%
• EPS Growth: -349.41%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 180,409,180
• 10 Day Avg. Volume: 23,955
• 30 Day Avg. Volume: 40,052
• PEG Ratio: <0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.81
• P/FCF Ratio: 15.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: C$0.30 ▼(-5.31% Downside)

Vext Science's overall score is driven by positive technical momentum and earnings call insights, despite weak financial performance and valuation. Revenue growth and cash flow improvements are promising, but profitability challenges and market pressures in Arizona weigh heavily on the score.

Positive Factors

Sustained revenue growth

High, recurring revenue growth driven by expansion in Ohio demonstrates demand traction and scalable retail footprint. Sustained top-line momentum supports reinvestment in stores and cultivation, improving long-term prospects if margins and yields continue to improve.

Consistent positive operating cash flow

Consecutive positive operating cash flow shows the business is generating internal liquidity to fund operations and expansion without heavy reliance on external financing. This enhances financial flexibility and supports a capital-light growth strategy over the medium term.

Improving cultivation yields

Sustained yield improvements reduce unit cost of goods sold and can sustainably expand gross margins if scaled. Higher cultivation efficiency supports margin recovery and competitive pricing, strengthening long-term cost competitiveness across retail and wholesale channels.

Negative Factors

Negative net profitability

Deep, persistent net losses indicate structural profitability issues; converting revenue growth into sustainable profits is necessary to secure shareholder returns and avoid recurring capital raises, which could dilute equity and hinder long-term value creation.

Negative return on equity

A materially negative ROE signals the company is not earning adequate returns on invested capital. Over months this can limit access to capital, reduce investor confidence, and force strategic changes if management cannot improve asset efficiency and profitability.

Arizona price/wholesale margin pressure

Structural pricing pressure in a mature market like Arizona undermines margins and the value of biological inventory. Persistent wholesale price declines can erode profitability across segments and require cost or mix shifts to sustain long-term earnings.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science (VEXT) is a diversified cannabis company operating in the legal cannabis market, primarily focused on the production and sale of high-quality cannabis products. The company operates in multiple sectors, including cultivation, processing, and retail, providing a range of products such as flower, oils, edibles, and other cannabis-infused goods. Vext Science aims to deliver innovative and effective solutions to consumers while adhering to regulatory standards and promoting responsible use.

How the Company Makes Money

Vext Science generates revenue through several key streams, including the sale of its cannabis products directly to consumers via its retail outlets and through wholesale distribution to other dispensaries. The company capitalizes on its cultivation and processing capabilities to ensure a steady supply of high-quality cannabis, which helps maintain competitive pricing and product availability. Additionally, Vext Science may explore strategic partnerships with other businesses in the cannabis sector, enhancing its distribution channels and product offerings. Factors contributing to its earnings include market demand for cannabis products, effective branding and marketing strategies, and compliance with evolving regulations in the cannabis industry.

Vext Science Financial Statement Overview

Summary

Vext Science shows revenue growth but struggles with profitability and operational efficiency. The balance sheet is moderately stable with manageable leverage, but negative return on equity is concerning. Cash flow management is improving, yet the company needs to convert cash generation into sustainable profits.

Income Statement

Vext Science shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data reveals a gross profit margin of 30.02%, which is a decline from previous years, indicating pressure on cost management. The net profit margin is negative at -37.43%, reflecting significant losses, although there is a positive revenue growth rate of 8.34% in the TTM period. The EBIT and EBITDA margins are also concerning, with EBIT being negative, suggesting operational inefficiencies. Overall, while revenue is growing, profitability remains a challenge.

Balance Sheet

The balance sheet of Vext Science indicates moderate financial stability. The debt-to-equity ratio stands at 0.50 in the TTM period, showing a manageable level of leverage. However, the return on equity is negative at -21.73%, highlighting inefficiencies in generating returns for shareholders. The equity ratio is relatively stable, suggesting a balanced capital structure. The company needs to improve its profitability to enhance shareholder returns.

Cash Flow

Cash flow analysis shows some positive trends for Vext Science. The TTM data indicates a free cash flow growth of 4.57%, and the operating cash flow to net income ratio is 0.58, suggesting some level of cash generation despite net losses. The free cash flow to net income ratio is 0.78, indicating that the company is generating cash relative to its net losses. While cash flow management appears to be improving, the company must focus on converting this into profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.83M	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	13.25M	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	6.17M	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-16.65M	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	128.09M	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	3.70M	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	35.06M	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	59.68M	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	68.41M	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	9.04M	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	12.53M	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-5.59M	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-6.08M	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Positive. The current price of 0.32 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.26, and above the 200-day MA of 0.22, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.51 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VEXT	59 Neutral	C$69.35M	-2.55	-21.73%	―	43.56%	-349.41%
CWEB	52 Neutral	C$94.06M	-3.76	-109.83%	―	-4.23%	37.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PLTH	49 Neutral	C$78.09M	-0.64	-83.55%	―	2.19%	-91.41%
AVCN	46 Neutral	C$24.18M	-12.50	-77.67%	―	2.41%	74.61%
LABS	45 Neutral	C$29.45M	-3.63	-19.10%	―	18.06%	34.58%
LEEF	39 Underperform	C$45.14M	-0.83	―	―	―	―

Vext Science Corporate Events

Vext Insider Jason Nguyen Trims Controlling Stake and Partially Repays Company Debt

Major shareholder Jason T. Nguyen has reduced his stake in Vext Science, Inc. following a share conversion and sale transaction that modestly diluted his ownership while leaving him as the controlling shareholder. Nguyen sold 20,340 Class A Multiple Voting Shares, which were converted into Subordinate Voting Shares under the company’s articles, cutting his holdings from 73.3% to 72.5% of the Multiple Voting Shares and from about 20.5% to 19.7% of the Subordinate Voting Shares on a partially diluted basis. The US$305,100 in proceeds was paid to Vext as partial repayment of a promissory note, slightly improving the company’s balance sheet while signaling that Nguyen, who remains a dominant insider, may adjust his position in the future depending on market and financing conditions.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Reports Corrected Q3 2025 Financials with Strong Revenue Growth

Vext Science, Inc. reported corrected financial results for Q3 2025, revealing a revenue increase of 41% year-over-year to $12.7 million, driven by expanded operations in Ohio and steady performance in Arizona. Despite earlier inaccuracies in financial metrics, the company demonstrated strong operational discipline, with a year-to-date operating cash flow of $8.5 million. Vext plans to continue expanding its Ohio dispensary footprint and anticipates improved cash flow in Q4, positioning itself for sustainable growth and long-term shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.20 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Secures Strong Shareholder Support at Annual Meeting

Vext Science, Inc. announced the successful voting results from its annual general meeting, with over 97% of votes cast in favor of all resolutions. This strong shareholder support reflects confidence in the company’s strategic direction and operations, potentially strengthening its position in the cannabis industry.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.23 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Sees 41% Revenue Growth in Q3 2025 Amid Ohio Expansion

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded operations in Ohio and strong performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year’s negative cash flow. Vext is on track to expand its Ohio retail locations to eight by 2026, positioning itself to capitalize on the state’s growing cannabis market. The company’s disciplined operations and strategic expansion are expected to drive sustainable growth and long-term value for shareholders.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Achieves 41% Revenue Growth in Q3 2025

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded retail operations in Ohio and consistent performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year. Vext’s strategic focus on Ohio’s adult-use market is evident as it strengthens its retail presence with plans to reach the state dispensary license cap by 2026. This expansion positions Vext to capture sustained growth and leverage its vertically-integrated platform for long-term shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science to Release Q3 2025 Financial Results on November 20

Vext Science, Inc. announced it will release its Q3 2025 financial results on November 20, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction in the competitive cannabis industry.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.